ARID1A determines luminal identity and therapeutic response in estrogen-receptor-positive breast cancer
- 13 January 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Genetics
- Vol. 52 (2), 198-207
- https://doi.org/10.1038/s41588-019-0554-0
Abstract
Mutations in ARID1A, a subunit of the SWI/SNF chromatin remodeling complex, are the most common alterations of the SWI/SNF complex in estrogen-receptor-positive (ER+) breast cancer. We identify that ARID1A inactivating mutations are present at a high frequency in advanced endocrine-resistant ER+ breast cancer. An epigenome CRISPR–CAS9 knockout (KO) screen identifies ARID1A as the top candidate whose loss determines resistance to the ER degrader fulvestrant. ARID1A inactivation in cells and in patients leads to resistance to ER degraders by facilitating a switch from ER-dependent luminal cells to ER-independent basal-like cells. Cellular plasticity is mediated by loss of ARID1A-dependent SWI/SNF complex targeting to genomic sites of the luminal lineage-determining transcription factors including ER, forkhead box protein A1 (FOXA1) and GATA-binding factor 3 (GATA3). ARID1A also regulates genome-wide ER–FOXA1 chromatin interactions and ER-dependent transcription. Altogether, we uncover a critical role for ARID1A in maintaining luminal cell identity and endocrine therapeutic response in ER+ breast cancer.Funding Information
- EIF | Stand Up To Cancer
This publication has 65 references indexed in Scilit:
- Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancyNature Genetics, 2013
- Comprehensive molecular portraits of human breast tumoursNature, 2012
- Whole-genome analysis informs breast cancer response to aromatase inhibitionNature, 2012
- The landscape of cancer genes and mutational processes in breast cancerNature, 2012
- Fast gapped-read alignment with Bowtie 2Nature Methods, 2012
- FIMO: scanning for occurrences of a given motifBioinformatics, 2011
- FOXA1 is a key determinant of estrogen receptor function and endocrine responseNature Genetics, 2010
- Biological determinants of endocrine resistance in breast cancerNature Reviews Cancer, 2009
- FoxA1 Translates Epigenetic Signatures into Enhancer-Driven Lineage-Specific TranscriptionCell, 2008
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001